Chetan Lathia

Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Lawrence H. Schwartz, Sergio Ricci et al. · Journal of Clinical Oncology · 2006 · 1.2K citations · Full text

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · Journal of Clinical Oncology · 2009 · 1.1K citations · Full text

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

Josep M. Llovet, Carol E. Peña, Chetan Lathia et al. · Clinical Cancer Research · 2012 · 557 citations · Full text

Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors

Jeffrey W. Clark, Joseph P. Eder, David P. Ryan et al. · Clinical Cancer Research · 2005 · 338 citations

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

Malcolm J. Moore, Holger W. Hirte, Lillian L. Siu et al. · Annals of Oncology · 2005 · 301 citations

Medicine, Pharmacology, Days On/7 Days +6